Skip to content

Propofol Anesthesia and Perinatal Outcome

Association of Maternal and Neonatal Umbilical Cord Blood Levels of Propofol Administered for Induction of General Anesthesia With Perinatal Findings in Gravidas Undergoing Cesarean Section

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07035899
Acronym
PA-Perinatal-O
Enrollment
102
Registered
2025-06-25
Start date
2023-08-01
Completion date
2024-12-30
Last updated
2025-06-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anesthesia, Pregnancy Complications

Keywords

Propofol, Pregnancy, Cesarean delivery, Perinatol outcome

Brief summary

The effects of intravenous propofol administration for general anesthesia in cesarean deliveries on maternal and infant health will be evaluated in relation to maternal and umbilical cord blood propofol levels.

Detailed description

After the ethics committee approval was obtained, volunteers who met the criteria for inclusion in the study were included in the study after obtaining their written permission. After the patients were taken to the operating room, IV catheterization was achieved after CTA, TA and sPO2 monitoring, and the patient was intubated 2 minutes after induction of propfol at 3 mg/kg and rocuronium at 0.6 mg/kg. After the baby was born, an intravenous blood sample was taken from the umbilical cord and the mother simultaneously. After the venous blood samples were obtained as 3 μL, the serum samples obtained by centrifugation as standard were portioned in equal volume to 500 μL Eppendorf tubes and stored at -80°C. After this pre-treatment, propofol was subjected to measurement tests with HPLC, and the collected data were added

Interventions

DRUGCaesarean Section

Cesarean section was performed as routine surgical procedure

Sponsors

Haseki Training and Research Hospital
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
SINGLE (Outcomes Assessor)

Intervention model description

Observational

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 40 Years
Healthy volunteers
No

Inclusion criteria

* Being pregnant in ASA category 1-2 * \>39 weeks of healthy pregnancy * \>28 weeks complicated pregnancy * Cesarean delivery with or without action * Providing induction of general anesthesia with intravenous propofol

Exclusion criteria

* Pregnant women under the age of 18, * Those who have stillbirth, * Severe chronic kidney and liver disease, * Neurological disease * Those with other systemic diseases

Design outcomes

Primary

MeasureTime frameDescription
Blood propofol concentrationThe first 5 minutes of cesarean deliveryng/ml

Countries

Turkey (Türkiye)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026